An observational study in Tricuspid Regurgitation, Tricuspid Valve Insufficiency and Tricuspid Insufficiency, sponsored by P+F Products + Features GmbH. Recruiting at 28 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.
Sponsored by P+F Products + Features GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Tricuspid Valve Insufficiency with a site in Spain — 7 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Spain.
Among the 13 studies in Tricuspid Valve Insufficiency with a site in Spain, this one is one of 2 that started in 2022, is one of 8 observational ones, and was the 8th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →7 of the 13 studies in Tricuspid Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Spain, United States, France and 2 more countries
Ages 18+
Edwards Lifesciences · Sites in Spain, Germany, Greece and 3 more countries
Montefiore Medical Center · Sites in Spain, United States, Canada and 5 more countries
Ages 18+
VDyne, Inc. · Sites in Spain, Australia, Austria and 8 more countries
Ages 18+
Abbott Medical Devices · Sites in Spain, United States, Estonia and 4 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 450 is above the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 98 across the 5 interventional studies, 531 across the 8 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 7 most frequent:
P+F Products + Features GmbH is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
P+F Products + Features GmbH has 3 studies filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Tricuspid Valve Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825898Ottawa Heart Institute Research CorporationOutcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment | 2026-12 |
| NCT05797519VDyne, Inc.Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Tricuspid Valve Insufficiency with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.
The study shall enrol subjects who were treated with the TricValve® Transcatheter Bicaval Valves System® in the Inferior Vena Cava and Superior vena cava. On compliance with the inclusion / exclusion criteria the subject will be enrolled for the observational study.
The study duration for the individual subject will be up to 5 year follow up. The follow-up should be made through pre-established periodic clinical consultations at discharge, 1 month, 6 months, 1 year follow up to 5 years after the procedure. In the consultations, routine exams such as hemogram, renal function, electrocardiogram and echocardiography in order to ascertain the bioprosthesis functioning and its hemodynamic profile are documented as per clinical routine practise.
The study shall enrol subjects who were treated with the TricValve® Transcatheter Bicaval Valves System® in the Inferior Vena Cava and Superior vena cava. On compliance with the inclusion / exclusion criteria the subject will be enrolled for the observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of patients with readmission for HF
First unplanned readmission for Heart Failure
Time frame: up to 12 months
All cause mortality
Number of patients in terms of all cause mortality
Time frame: up to 30 days, up to 6 months, up to 5 years
Percentage of participants with major adverse events
Percentage of participants with major adverse events
Time frame: up to 12 months
Number of participants with severe adverse events
Number of participants with severe adverse events
Time frame: up to 30 days, up to 6 months, up to 5 years
Number of patients with readmission for HF
First unplanned readmission for Heart Failure
Time frame: up to 5 years
NYHA functional class
Change of New York Heart Association (NYHA) functional class from III or IV to a lower one
Time frame: up to 30 days, up to 6 months, up to 5 years
Change in BNP/NTproBNP and diuretic dosage
Change in BNP/NTproBNP and diuretic dosage before intervention after intervention
Time frame: up to 12 months
Change of the right atrium size
Change of the Right Atrium Size assessed by echocardiography
Time frame: up to 30 days, up to 6 months, up to 5 years
Change of the free valve movement
Change of the free valve movement assessed by echocardiography
Time frame: up to 30 days, up to 6 months, up to 5 years
Valve Device Regurgitation
Number of patients with valve device regurgitation assessed by echocardiography
Time frame: up to 30 days, up to 6 months, up to 5 years
Number of alive patients
Number of alive patients free from reintervention related to TricValve System
Time frame: up to 30 days, up to 6 months, up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.
Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 44 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →
P+F Products + Features GmbH